Abstract
The recent advice to doctors from the Medicines and Healthcare products Regulatory Agency (MHRA) to stop prescribing a whole class of drugs (selective COX-2 inhibitors) has come as something of a shock to most people. For patients who have been taking these drugs – well over 1 million people according to press reports – it has been a source of considerable concern.It will also have further shaken the public's already weakened trust in the MHRA's ability to protect them from big business (i.e. pharmaceutical companies).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
